AGM Statement

Immunodiagnostic Systems Holdings plc

AGM Statement

Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading producer of diagnostic testing kits for the clinical and research markets, will hold its Annual General Meeting today at 3.00pm at the offices of Brewin Dolphin Limited at 12 Smithfield Street, London EC2A 9BD. At the meeting Chairman David Evans will make the following statement:

"Trading for the Company continues to be in-line with management expectations with demand for both our manual products and the IDS-iSYS being greater than the same period last year.

We have introduced recent software upgrades and an increased sample capacity capability for the IDS-iSYS, and these have been well received by the market.

Following receipt of our 510(k) clearance from the US FDA and a successful exhibition at the AACC meeting in California we have now secured our first 2 USA accounts. These two accounts will have a combined annual income of circa $500k. IDS Inc. has a full evaluation book and expects more live accounts by the end of H1.

Post-launch we have sold or placed on reagent rental basis 115 IDS-iSYS instruments and the directors expect this number to increase throughout the remainder of the year."

A more detailed trading update for H1 will be issued week commencing 4 October.

For further information:

End.